Abstract: The DRMs most frequent were M184I/V (82.9%) for nucleoside reverse transcriptase inhibitors (NRTI), K103N/S (63.4%) for nonnucleoside reverse transcriptase inhibitor (NNRTI), and V82A/L/M (7.3%) for protease inhibitors (PI).
Result: Only half of the individuals had used PI (n = 46/82), only 17% of individuals presented DRMs associated with protease inhibitors (n = 14), and the most frequent mutations were V82A/L/M (6/82; 7.3%) and I54L/M/V (5/82; 6%),
Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.
Result: The PI-SDRMs with the lowest treatment/naive prevalence ratios were F53Y (5-fold), V82L (7-fold), M46L (9-fold), and I85V (14-fold).
Discussion: Four PI-SDRMs (M46L, F53Y, V82L, and I85V) had relatively low treated/naive prevalence ratios.
Discussion: Moreover, F53Y, V82L, and I85V have not been linked to reduced susceptibility to the currently used PIs raising the question of whether these mutations will remain useful for the ongoing surveillance of clinically meaningful transmitted PMID: 32267869
2020
PloS one
Table: V82L
Discussion: In line with this, the only isolate with V82L mutation in this study, NG_IM.12_07, also harbours N88D mutation in addition to L10I and K20I mutations.
Discussion: The frequency of occurrence (10.7%) of major PI resistance mutations, M46L and V82L, obtained in this study is somewhat lower than the 39.1% recorded in a similar study conducted by Odaibo et al.
Discussion: The only isolate with intermediate-level resistance to these drugs had V82L major PI resistance mutation as well as L10I and N88D minor PI
Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China.
Discussion: However, in the presence of G48V flap mutation, mutations of residue 82 to larger side chains like
Discussion: The side chains of mutations vary in size from the smaller V82A to bulkier V82F in addition to V82S, V82T, V82L, and V82I that are in between.
Discussion: With P3 Arg bound at the preferred wild-type flap-binding site, mutations at 82 with large side chains like V82F, V82I, or V82L hinder the binding of PR inhibitors, thereby altering PR susceptibility to PIs while retaining binding to substrates.
Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population.
Result: Of the 203 PI-associated SDRMs, the most common were L90M (33.5%), M46I/L (19.7%), I54V (10.8%), V82A/L/T (10.4%), and D30N plus N88D (9.8%).
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
PMID: 31430369
2019
The Journal of antimicrobial chemotherapy
Method: Primary PI-R substitutions were D30N, V32I, M46I/L, I47V/A, G48V, I50V/L, I54M/L, Q58E, T74P, L76V, V82A/F/L/S/T, N83D, I84V, N88S and L90M in PR.
Table: V82A/L
Molecular Genetics and the Incidence of Transmitted Drug Resistance Among Pre-Treatment HIV-1 Infected Patients in the Eastern Cape, South Africa.
Abstract: Four major protease inhibitor (PI) related mutations (I54V, V82A/L, L76V and L90M) were observed in seven patients while several other minor and accessory PIs were also identified.
Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study.
Method: Participants with a history of genotypic/phenotypic drug resistance to protease inhibitors (PIs) or with HIV-1 genotypic drug resistance to PIs at baseline (including D30N, M46I/L, I47V/A, G48V, I50L, I54M/L, Q58E, T74P, L76V, V82A/F/L/T/S, N83D, I84V, N88S, or L90M) were excluded, despite any reported effects of PI resistance or resistance
[Genetic analysis of the mutations in HIV-1 infected population in Ecuador].
PMID: 29652972
2018
Revista chilena de infectologia
Abstract: Results The most frequent mutations were M184V/I, K101E/P/H, K103N/S, D30N, M46L/I, I54L/M, V82T/F/A/S/L and L90M in adults and F77L, K103N/S, M46L/I, V82T/F/A/S/L and L90M in children.
HIV mutation literature information.
PMID: 
2021
BioMed research international
Browser Board
Co-occurred Entities
Filtrator
ViMRT